1. Home
  2. OCUP vs VATE Comparison

OCUP vs VATE Comparison

Compare OCUP & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCUP
  • VATE
  • Stock Information
  • Founded
  • OCUP 2018
  • VATE 1994
  • Country
  • OCUP United States
  • VATE United States
  • Employees
  • OCUP N/A
  • VATE N/A
  • Industry
  • OCUP Biotechnology: Pharmaceutical Preparations
  • VATE Metal Fabrications
  • Sector
  • OCUP Health Care
  • VATE Industrials
  • Exchange
  • OCUP Nasdaq
  • VATE Nasdaq
  • Market Cap
  • OCUP 53.1M
  • VATE 49.2M
  • IPO Year
  • OCUP N/A
  • VATE 1996
  • Fundamental
  • Price
  • OCUP $1.22
  • VATE $4.88
  • Analyst Decision
  • OCUP Strong Buy
  • VATE
  • Analyst Count
  • OCUP 3
  • VATE 0
  • Target Price
  • OCUP $18.67
  • VATE N/A
  • AVG Volume (30 Days)
  • OCUP 90.4K
  • VATE 91.5K
  • Earning Date
  • OCUP 11-11-2024
  • VATE 11-07-2024
  • Dividend Yield
  • OCUP N/A
  • VATE N/A
  • EPS Growth
  • OCUP N/A
  • VATE N/A
  • EPS
  • OCUP N/A
  • VATE N/A
  • Revenue
  • OCUP $16,449,000.00
  • VATE $1,364,600,000.00
  • Revenue This Year
  • OCUP N/A
  • VATE N/A
  • Revenue Next Year
  • OCUP $258.69
  • VATE N/A
  • P/E Ratio
  • OCUP N/A
  • VATE N/A
  • Revenue Growth
  • OCUP N/A
  • VATE N/A
  • 52 Week Low
  • OCUP $1.15
  • VATE $3.25
  • 52 Week High
  • OCUP $3.40
  • VATE $15.50
  • Technical
  • Relative Strength Index (RSI)
  • OCUP 44.79
  • VATE 50.40
  • Support Level
  • OCUP $1.24
  • VATE $3.25
  • Resistance Level
  • OCUP $1.34
  • VATE $4.16
  • Average True Range (ATR)
  • OCUP 0.08
  • VATE 0.23
  • MACD
  • OCUP 0.00
  • VATE 0.05
  • Stochastic Oscillator
  • OCUP 12.00
  • VATE 73.08

About OCUP Ocuphire Pharma Inc.

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting stations across the United States.

Share on Social Networks: